This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/usa/344239-monsanto-bayer-bid-reject/

The article has changed 3 times. There is an RSS feed of changes available.

Version 0 Version 1
Monsanto rejects $62 million bid from Bayer Monsanto rejects $62bn bid from Bayer
(35 minutes later)
GMO giant Monsanto rejected a $62 billion takeover bid by the German pharmaceutical Beyer, saying the price was too low but adding it remained “open to further talks.” GMO giant Monsanto rejected an unsolicited $62 billion takeover bid by German pharmaceutical giant Bayer, saying the price was too low but adding that it remained “open to further talks.”
Monsanto can “see the logic” of combining with the German corporation, and believes the merger could get the required approval from regulators, sources familiar with the talks told Reuters. However, the St. Louis, Missouri-based company believes its shareholders deserve a better offer.
READ MORE: Germany’s Bayer makes $62bn offer to buy US firm Monsanto
“The deal will allow Bayer to tap growing demand at a time when farmers must boost food productivity to feed an estimated 10 billion people worldwide by the year 2050,” RT America’s Ashlee Banks said, adding that Bayer CEO Werner Baumann hopes that this rationale will win over skeptical investors and overcome anti-GMO backlash.
Some Bayer shareholders were critical of the bid, saying the $122 per share was too high already. Monsanto’s shares rose to $107.61 on the New York Stock Exchange on Tuesday morning, short of Bayer’s valuation.
Meanwhile, Bayer’s shares rose by 3.23 percent, reaching 87.15 Euros at the Frankfurt exchange.
The German conglomerate now has to decide whether to raise the offer, walk away, or attempt a hostile takeover.
"I don't think they will get it at $122 because I don’t think Monsanto will set that price," Andrea Williams, fund manager at Royal London Asset Management, told Bloomberg. "The danger is that you start then having discussions about how you are going to fund the higher offer, because they are already stretching the balance sheet.”
If successful, the deal would eclipse the planned combination of the agricultural units of Dow Chemical and DuPont, and would also become the biggest-ever corporate buyout by a German company.